tiprankstipranks
Trending News
More News >

Xinhua Pharmaceutical Secures Approval for Cobamamide Capsules License Transfer

Story Highlights
Xinhua Pharmaceutical Secures Approval for Cobamamide Capsules License Transfer

Don’t Miss TipRanks’ Half-Year Sale

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.

Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder of its Cobamamide Capsules. This approval follows a contract signed with Beijing Baiya United Pharmaceutical Research Institute, transferring the marketing authorization holder status and related technical rights to Xinhua Pharmaceutical, enhancing its market position and operational capabilities.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in the People’s Republic of China, focusing on the production and marketing of prescription drugs. The company is involved in the development and commercialization of pharmaceutical products, with a particular emphasis on prescription medications.

Average Trading Volume: 4,872,574

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.4B

For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1